World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
44068
World Ranking
14368
National Ranking
8

Eva Havrdova publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eva Havrdova sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 617 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Eva Havrdova D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eva Havrdova sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Eva Havrdova is affiliated with Charles University in the Czech Republic and has contributed extensively to the field of medicine, with a primary focus on multiple sclerosis research and related neurological disorders. Their work spans over several years and includes a substantial number of scientific publications and collaborations within the medical community.

Their research covers a range of topics, predominantly:

  • Multiple Sclerosis Research Studies
  • Peripheral Neuropathies and Disorders
  • Polyomavirus and related diseases
  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • Acute Lymphoblastic Leukemia research
  • Autoimmune and Inflammatory Disorders Research

The main fields of study include medicine with an emphasis on pathology and forensic medicine, neurology, oncology, rheumatology, and immunology. This multidisciplinary approach is reflected in their publication record and topics of investigation.

Eva Havrdova has authored or co-authored numerous papers, including notable recent publications such as:

  • "Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study" (2020) published in The Lancet Neurology
  • "Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study" (2021) published in JAMA Neurology
  • "The potential of serum neurofilament as biomarker for multiple sclerosis" (2021) published in Brain
  • "Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis" (2020) published in Multiple Sclerosis Journal
  • "Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis" (2021) published in Journal of Neurology

Their frequent co-authors indicate a collaborative research network within the neurological and multiple sclerosis research communities and include:

  • Dana Horáková
  • Tomáš Kalinčík
  • Helmut Butzkueven
  • Jeannette Lechner-Scott
  • Serkan Özakbaş

Eva Havrdova's work is frequently published in established scientific journals, with the most frequent venues being:

  • Neurology
  • Multiple Sclerosis and Related Disorders
  • Multiple Sclerosis Journal
  • Journal of Neurology Neurosurgery & Psychiatry
  • JAMA Neurology

Best Publications

  • Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

    Chris H Polman;Stephen C Reingold;Brenda Banwell;Michel Clanet

  • A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

    Chris H. Polman;Eva Havrdova;Michael Hutchinson;Ludwig Kappos

  • Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

    Robert J Fox;David H Miller;J Theodore Phillips;Michael Hutchinson

  • Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

    Jeffrey A. Cohen;Alasdair J. Coles;Douglas L. Arnold;Christian Confavreux

  • Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

    Alasdair J. Coles;Cary L. Twyman;Douglas L. Arnold;Jeffrey A. Cohen

  • ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

    X. Montalban;R. Gold;A. J. Thompson;S. Otero‐Romero

  • Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

    Ludwig Kappos;Ralf Gold;David H Miller;David G MacManus

  • Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis

    J. William L. Brown;J. William L. Brown;J. William L. Brown;Alasdair Coles;Dana Horakova;Eva Havrdova

  • Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

    Ludwig Kappos;David Bates;Gilles Edan;Mefkûre Eraksoy

  • Defining secondary progressive multiple sclerosis.

    Johannes Lorscheider;Johannes Lorscheider;Katherine Buzzard;Katherine Buzzard;Katherine Buzzard;Vilija G Jokubaitis;Vilija G Jokubaitis;Tim Spelman

  • Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

    Eva Havrdova;Steven Galetta;Michael Hutchinson;Dusan Stefoski

  • Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

    Anna He;Bernd Merkel;James William L Brown;James William L Brown;James William L Brown;Lana Zhovits Ryerson

  • The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL

    P. A. Calabresi;G. Giovannoni;C. Confavreux;S. L. Galetta

  • MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

    D. H. Miller;D. Soon;K. T. Fernando;D. G. MacManus

  • Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

    G Giancarlo Comi;A. Pulizzi;Marco Rovaris;O. Abramsky

  • Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

    Elena H. Martinez-Lapiscina;Sam Arnow;James A. Wilson;Shiv Saidha

  • Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

    A.S. Fassas;J. R. Passweg;A. Anagnostopoulos;A. Kazis

  • Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

    J. Kuhle;G. Disanto;R. Dobson;R. Adiutori

  • Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

    Per Soelberg Sorensen;Steen Lisby;Richard Grove;Frederick Derosier

  • Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

    Ralf Gold;Gavin Giovannoni;Krzysztof Selmaj;Eva Havrdova

Frequent Co-Authors

Krzysztof Selmaj
Krzysztof Selmaj University of Warmia and Mazury in Olsztyn
Gavin Giovannoni
Gavin Giovannoni Queen Mary University of London
Helmut Butzkueven
Helmut Butzkueven Monash University
Douglas L. Arnold
Douglas L. Arnold Montreal Neurological Institute and Hospital
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Hans-Peter Hartung
Hans-Peter Hartung Heinrich Heine University Düsseldorf
Maria Trojano
Maria Trojano University of Bari Aldo Moro
Robert Zivadinov
Robert Zivadinov University at Buffalo, State University of New York
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Raymond Hupperts
Raymond Hupperts Maastricht University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending medical school. There are several accelerated healthcare administration degree programs online, ideal for those seeking healthcare leadership roles without investing years in education.

Nursing professionals can advance quickly by enrolling in adn to np programs online. These bridge programs help registered nurses with an associate degree move seamlessly into becoming nurse practitioners.

For those interested in wellness and preventive care, an online degree nutrition provides the knowledge needed for careers in dietetics, public health, and health education.

Aspiring healthcare managers can prepare for high-level roles by choosing online mha programs. Many of these programs are CAHME-accredited, ensuring quality and recognition in the field.

Whether your path is clinical or administrative, these online degrees offer flexible options for building a rewarding healthcare career.

Best Scientists Citing Eva Havrdova

Trending Scientists

Recently Published Articles